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A B ST R AC T  
 
Aim: Levothyroxine (L-T4) requirements in obese hypothyroid patients receiving L-T4 therapy decrease 
following bariatric surgery. L-T4 absorption is also thought to decrease after surgery. The purpose of this study 
was to evaluate L-T4 requirements in hypothyroidism cases before and after weight loss through bariatric 
surgery. 
Methods: Seventy-six cases of hypothyroidism receiving L-T4 replacement therapy and with a body mass 
index over 40 kg/m2 were included in the study. Patients losing at least 10% of basal body weight following 
bariatric surgery were assessed in terms of thyroid hormone levels and L-T4 requirements over follow-up of 
at least one year. The L-T4 requirements of patients in whom euthyroidism was achieved were compared in 
terms of bariatric surgery procedures and hypothyroidism etiology.  
Results: Seventy-six patients (56 women, 20 men) with a mean age of 38 years (18-51) were included in the 
study. Mean weight before bariatric surgery was 121.6 ± 6.8 kg, and mean body mass index was 49.5 ± 1.6 
kg/m2. Euthyroidism was confirmed at pre- and post-bariatric surgery evaluation. No statistically significant 
postoperative changes were determined in thyroid-stimulating hormone or free thyroxine-3 and -4 (p > 0.05). 
A statistically insignificant decrease was observed in L-T4 dosages after surgery in cases of Hashimoto’s 
thyroiditis (p = 0.064). A statistically significant decrease was determined in L-T4 dosages in cases of non-
Hashimoto hypothyroidism (p = 0.001). L-T4 requirements decreased in both surgical procedures (p = 0.001) 
Conclusion: Postoperative L-T4 requirements decrease with weight loss. In addition, no decrease appeared to 
occur in L-T4 absorption following the surgical procedures in this study.  
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Introduction 
Obesity is one of the most important present-
day health risks.  Hypothyroidism is commonly 
observed in obese populations [1]. Clinical and 
subclinical hypothyroidism leads to weight gain 
due to a decrease in basal metabolism rates. 
According to common perception, 
hypothyroidism is responsible for 
obesity. However, establishing a causal link 
between the two is controversial. Recent 
observations indicate that changes in thyroid-
stimulating hormone (TSH) may well be 
secondary to obesity. At the same time, the 
replacement dose of Levothyroxine (L-T4) can 
be modified [2]. 
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Drug absorption may be deficient in association 
with the type of bariatric surgery performed. 
Drug absorption deficiency can lead to an 
increased L-T4 requirement in hypothyroid 
patients. However, the data concerning this are 
inconsistent [3]. Research has shown that obese 
hypothyroid patients require higher L-T4 
dosages than normal weight individuals [4]. L-
T4 dosages decrease following weight loss [5]. 
However, it may be necessary to increase the 
dosages due to the possibility of resection-
related reduced drug absorption. 
Decreased L-T4 requirements have recently 
been shown in the majority of hypothyroid 
patients in line with weight loss achieved with 
modern bariatric surgery. The purpose of the 
present study was to investigate the effect of 
weight loss following bariatric surgery 
performed using mini-gastric bypass and sleeve 
gastrectomy procedures on L-T4 requirements 
in hypothyroid patients.   
 
Materials and Methods 
This study was performed in compliance with 
the Declaration of Helsinki and was approved 
by the Ethics Committee of the Medicana 
International Samsun Hospital, Turkey 
(12.08.2020-9/7109). 
The research concerned 76 patients. The study 
group occurred of adult (over 18 years) 
hypothyroid patients (Hashimoto’s thyroiditis, 
thyroidectomy, radioactive iodine ablation 
therapy, congenital hypothyroidism, central 
hypothyroidism, post-subacute thyroiditis, or 
infiltrative causes) receiving L-T4 replacement 
therapy under follow-up in our endocrinology 
and obesity surgery department, with body 
mass index exceeding 40 kg/m2 (class 3 
obesity), and undergoing bariatric surgery. 
Patients were assessed using thyroid gland 
ultrasonography in order to avoid diagnostic 
confusion. 
Patients with known thyrotoxicosis during 
screening, with primary endocrine/systemic 
disease, any inflammatory disease other than 
Hashimoto’s thyroiditis, celiac disease and 
malabsorption, inflammatory gastrointestinal 
diseases, cancer, history of use of other 
medications reducing drug absorption, or 
receiving radiotherapy to the neck and head 
region were excluded. In the light of the study 
aims, patients achieving weight loss of at least 
10% from baseline following bariatric surgery 
were evaluated in terms of thyroid hormone 
levels and LT-4 requirements initially and over 
a 12-month follow-up period at intervals of 2-3 
months.  
Patients were given detailed instruction 
concerning L-T4 use and asked to take the drug 
as described one hour before breakfast. The 
importance of the timing of L-T4 use was 
emphasized, particularly in cases using 
multivitamins and proton pump inhibitors in the 
postoperative period. Cases using the drug 
irregularly or frequently forgetting to take L-T4 
were placed under close monitoring, and 
thyroid hormones were evaluated during 
periods when L-T4 was used regularly. If TSH 
values were below 2.5 mIU/L in cases losing 
more than 10% of body weight following 
bariatric surgery, the L-T4 dosage was reduced 
by 25%. The dosage was decreased by 30% in 
cases with TSH below 1 mIU/L at postoperative 
follow-up.  
Hormonal data for TSH (normal range 0.35-
4.94 mIU/L), free thyroxine-4 (fT4; normal 
range: 9.01-19.05 pmol/L), free 
triiodothyronine (fT3; normal range: 3.5-8.0 
pmol/L), albumin (normal range: 3.5-5.5 g/dL), 
thyroglobulin antibody (TgAb; normal range: 
0-4.11 lU/mL), and thyroid peroxidase 
antibody (TPOAb; normal range: 0-5.61 
IU/mL) levels were investigated using 
automated immune chemiluminometric assay 
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(ICMA) kits (Monmouth, UK). Thyroid 
ultrasonography was applied using a high 
resolution device (Philips Medical system, 
USA) equipped with a 5–12 MHz broadband 
linear array probe. All procedures were 
performed by an experienced operative.  
Statistical analysis 
Data analysis was performed on SPSS version 
21.0 software (SPSS Inc., Chicago, USA).  
Quantitative parametric data were expressed as 
mean plus standard deviation (SD), and 
quantitative non-parametric data as median 
values with minimum and maximum. The 
Kolmogorov Smirnov and Shapiro-Wilk test 
was used to analyze the distribution of 
variables. For non-parametric data, 
comparisons between different groups were 
performed using the Mann-Whitney U test, 
while the independent-t test was used to 
compare parametric data between the groups. 
 
Results  
Seventy-six patients (56 women, 20 men) with 
a median age of 38 years (18-51) were included 
in the research. Mini-gastric bypass was 
performed in 52 cases, and sleeve gastrectomy 
in 24. Postoperative follow-up time was 2.4 
(1.7-3.6) years. Hypothyroidism associated 
with the surgical procedure was present in 28 
cases, Hashimoto’s thyroiditis in 32, and 
hypothyroidism associated with other causes 
(radioactive iodine [RAI] intake, congenital 
hypothyroidism, post-subacute thyroiditis, or 
infiltrative causes) in 16. Patients’ mean weight 
before bariatric surgery was 121.6±6.8 kg, and 
mean body mass index was 49.5±1.6 kg/m2. 
Mean weight after bariatric surgery decreased 
to 94.6±5.6 kg and mean body mass index to 
33.3±1.4 kg/m2. Cases’ pre- and postoperative 
characteristics are shown in Table 1.  
All bariatric surgery procedures were 
performed using standard techniques by an 
experienced bariatric surgeon. Euthyroidism 
was confirmed at pre- and post-bariatric surgery 
checks. No statistical postoperative changes 
were determined in levels of the thyroid 
hormones TSH, fT4 or fT3 (p>0.05). We found 
a statistically significant decrease in L-T4 
dosages in parallel with weight loss after 
bariatric surgery in cases diagnosed with 
hypothyroidism developing after bariatric 
surgery and other hypothyroidism cases (RAI 
intake, congenital hypothyroidism, post-
subacute thyroiditis, and infiltrative causes) 
(p=0.001). We also determined a non-
significant decrease in L-T4 dosages in cases of 
Hashimoto’s thyroiditis (p=0.064). The 
decrease in L-T4 dosages was highly 
significant in both surgical procedures 
(p=0.001). The findings are shown in Table 2. 
Albumin levels also decreased, particularly in 























Table 1. Preoperative characteristics of the 
patients. 
Parameters n=76  
Age (years), median(min-max) 38 (18-51) 
Sex 
Female, n (%) 




Weight (kg), mean±SD 121.6±6.8 
BMI, kg/m2 49.5±1.6 














BMI: Body Mass Index, SD: Standard Deviation 
1RAI intake, congenital hypothyroidism, post-
subacute thyroiditis, infiltrative causes. 
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L-T4 dosage requirements decrease in parallel 
with weight loss in obese cases diagnosed with 
hypothyroidism. Loss of body mass eliminates 
anxiety concerning a decrease in L-T4 
absorption resulting from the operation. Newly 
evidence [5] and our own study data show that 
thyroid hormone requirements may decrease 
with weight loss in obesity. 
A few studies have determined significant 
decreases in TSH and fT3 levels with weight 
loss after obesity surgery. Weight loss also 
reduces thyroid hormone requirements [5]. 
Similarly in the present study, we found a 
statistically significant decrease in L-T4 



























T4 dosage requirements decrease in parallel 
with weight loss to yield similar TSH levels in 
both types of surgery. In our previous study we 
observed that TSH levels decreased in 
correlation with insulin resistance following 
bariatric surgery [6]. Juiz-Valiña et al. [7] also 
reported similar findings. We therefore think 
that L-T4 requirements decreased through a 
similar pathway to the decrease in insulin 
resistance occurring with weight loss in 
association with thyroid hormone resistance in 
obese patients. It possibly concluded that 
weight loss restores thyroid hormone 
homeostasis. Research has shown that severely 
obese individuals may require higher L-T4-
suppressing or replacement therapy than 
Table 2. Changes in thyroid function and L-thyroxine dosages following bariatric surgery. 





Weight (kg) (mean±SD) 121.6±6.8 94.6±5.6 0.001 
BMI (kg/m2) 49.5±1.6 33.3±1.4 0.001 
TSH (mIU/L)  2.1±0.5 1.9±0.4 0.652 
fT4 (pmol/L)  13.1 ± 0.8 14.9 ± 0.6 0.860 
fT3 (pmol/L)  4.6 ± 0.4 4.5 ± 0.8 0.972 
L-thyroxine,  mcg/day, dose 
Surgical hypothyroidism   
Hashimoto’s thyroiditis   
Other hypothyroidism1  
 











Albumin, g/dL  4.7±0.6 4.2±0.8 0.043 
Type of bariatric surgery,  
L-thyroxine,  mcg/day, dose 
            Mini-gastric bypass    














TSH, thyroid-stimulating hormone; fT4, free-T4; fT3, free-T3; RAI, radioactive iodine; SD: Standard 
Deviation. 1RAI intake, congenital hypothyroidism, post-subacute thyroiditis, infiltrative causes. 
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normal weight subjects in association with 
impairment of the L-T4 pharmacokinetic 
parameters [8].  
Decreased thyroid gene expression 
(particularly TSH-receptors) has been reported 
in visceral adipose tissue and subcutaneous in 
obese patients [9]. The decrease in adipose 
tissue in parallel with weight loss following 
obesity surgery results in corresponding 
changes in serum TSH and thyroid hormone 
levels. These changes show that adipocytes are 
involved in the regulation of thyroid hormones. 
Our research revealed that L-T4 dose 
requirements decreased in parallel with weight 
loss in cases of surgical hypothyroidism and 
other hypothyroidism cases. This finding 
suggested that the level of adverse effects on 
drug absorption caused the decrease in gastric 
acid in the sleeve gastrectomy group can be 
overlooked. In the mini gastric bypass cases, 
however, approximately 1/3 of the length of the 
intestine was bypassed. This method may have 
permitted sufficient drug absorption through 
the non-bypass intestine.  
Research has shown that L-T4 requirements 
decrease in the postoperative period. The 
principal correlation shown in research is 
between weight loss and dosage [1]. The 
principal L-T4 fluid formulation has been 
shown to be capable of preventing the problem 
of malabsorption after bariatric surgery in 
malabsorptive operations (Roux-en-Y gastric 
bypasses and biliary pancreatic diversions) 
[10]. Our findings showed no L-T4 
malabsorption in sleeve gastrectomy and mini 
gastric bypasses. Loss of both adipose and non-
adipose mass following these operations may 
result in a decrease in postoperative L-T4 
requirements by preventing absorptive effects 
resulting from surgery [11]. These studies have 
shown no decrease in L-T4 absorption in Roux-
en-Y bypasses. Small but significantly delayed 
L-T4 absorption has been observed after 
surgery in these cases [12]. 
Research involving sleeve gastrectomy and 
mini gastric bypasses has shown no significant 
L-T4 absorption in the gut, duodenum, or upper 
part of the jejunum [13]. These are bypassed or 
removed in bariatric surgery. These studies 
offer powerful support for our own findings. L-
T4 dosage requirements also decrease in 
parallel with weight loss. In contrast, although 
we observed a decrease in drug requirements in 
both types of operation in hypothyroidism cases 
associated with Hashimoto’s thyroiditis, this 
was not statistically significant. This variation 
may be due to an increase dose requirement 
deriving from the chronic progressive course of 
Hashimoto’s thyroiditis. Alternatively, these 
operations may have resulted in additional 
absorption insufficiency due to Hashimoto’s 
thyroiditis being frequently accompanied by 
celiac disease, inflammatory bowel disease, and 
autoimmune gastric diseases. We think that 
these factors may account for the decreased L-
T4 dosage requirements determined in other 




Both adipose and non-adipose body mass 
decrease with significant weight loss achieved 
with bariatric surgery. Marked weight loss 
results in a decrease in postoperative L-T4 
requirements. This decrease is more powerful 
than the effect of resection on absorption. This 
study shows that sleeve gastrectomy and mini 
gastric bypasses do not result in L-T4 
malabsorption. This study adds new findings to 
the actual evidence regarding changes caused 
by weight loss in thyroid morphology.  
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